The International Myeloma Society Meeting (IMS 2025) is the defining annual meeting in myeloma with a focus on both the basic, preclinical, and clinical aspects. This year’s program took place in Toronto, Canada, from September 17th to September 20th, 2025.
Notable takeaways from the event:
Rahul Banerjee, Assistant Professor at the University of Washington:
Huge thank you to Myeloma Society leadership
“Huge thank you to Myeloma Society leadership and MM field leaders for taking junior faculty under their wing.
Seeing the camaraderie in the myeloma field is always so inspiring, even if we can’t always agree on SMM treatment or even the units to measure FLC!”
“IMS25 with Elias K. Mai, the man who will some day be able to tell the world definitely whether CD38 + R outperforms R maintenance…
We both may have more gray hairs by the time the study reads out!”
“IMS25 4 different colors… enough to run flow cytometry, just not NGF.
Already learning so much about CAR-T AE management from a few minutes of talking to Surbhi Sidana, Yi Lin and Nisha Joseph.”
Andrew Yee presenting the Alliance trial on the big stage
“Kudos to Andrew Yee for presenting the Alliance trial on the big stage at Myeloma Society plenary!
Len 15mg (not 25mg) in this older ASCT-ineligible patient population.
Addressing the mismatch between trials and RW practice by implementing the latter into the former!
And even with lenalidomide 15mg as the starting dose, len RDI is low, especially for frail patients.
But – in support of down with dex – note that both frail and non-frail patients generally hated dex 40mg total weekly… de-escalation after 2 cycles may be the way forward!
And Zubingahvari came to the podium to make that very same point!”
Sridevi Rajeeve, Assistant Attending Physician, Myeloma and Cell Therapy Service at Memorial Sloan Kettering Cancer Center:
Important summary slide on CAR+ T-cell lymphomas
“Important summary slide on CAR+ T-cell lymphomas from the Immunotherapy session by Benjamin Puliafito. Comprehensive workup is needed for all post-CART toxicities, especially unusual signs and symptoms, given the heterogeneity of T-cell lymphoma manifestations.”
“Oral abstract session: results from the TANDEMM trial at Memorial Sloan Kettering Cancer Center by Dr. Sham Mailankody, presented by Saad Z. Usmani.
In heavily preTx RRMM, co-infusion of BCMA+GPRC5D CART as a dual agent targeting strategy was feasible, tolerable, and efficacious.”
Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal:
Huge congrats to Marivi Mateos
“Huge congrats to Marivi Mateos, recipient of the Waldenstrom Lifetime Achievement in Myeloma.
Pioneering work in early intervention and many other major advances in the field.”
Inspiring lecture by Leif Bergsagel
“Inspiring lecture by Leif Bergsagel, Mayo Clinic, after receiving the Ken Anderson Award at IMS25.
Leif has made huge contributions to our understanding of the biology of the disease. Congrats, Leif!”
“Winners of 2025 IMS Awards with Nikhil C. Munshi(Past President of the Society)
Marivi Mateos (Waldenstrom Lifetime Achievement)
Leif Bergsagel (Ken Anderson Award)
Elena Zamagni (Bart Barlogie Award).”
You can find more posts featuring IMS25 on OncoDaily.